Biotech: Page
-
IPO window
Parabilis sets a record with a $670M biotech IPO
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.
By Gwendolyn Wu • June 10, 2026 -
News roundup
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.
By BioPharma Dive staff • June 10, 2026 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
China competition
Amid a flurry of biotech deals, China looks to keep innovation at home
The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing game for foreign companies.
By Kelly Bilodeau • June 10, 2026 -
Emerging biotech
Stealthy startup Treeline plans a reverse merger
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
By Gwendolyn Wu • June 9, 2026 -
Emerging biotech
City banks nearly $100M for next-gen RNAi drugs
Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.
By Gwendolyn Wu • June 8, 2026 -
Tango data add to growing momentum for pancreatic cancer drugs
A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
By Jonathan Gardner • June 8, 2026 -
Emerging biotech
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
By Gwendolyn Wu • June 8, 2026 -
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
By Kelly Bilodeau • June 5, 2026 -
Alnylam, Inceptive ink AI deal potentially worth $2B
The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
By Kristin Jensen • June 4, 2026 -
An ADC specialist sinks on safety concerns for blood cancer drug
Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
By Delilah Alvarado • June 4, 2026 -
News roundup
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.
By BioPharma Dive staff • June 4, 2026 -
Emerging biotech
A Spanish biotech banks $87M to make differentiated ADCs
Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
By Gwendolyn Wu • June 4, 2026 -
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
By Jonathan Gardner • June 3, 2026 -
China competition
House bill aims to crack down on China biotech deals
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
By Kristin Jensen • June 3, 2026 -
News roundup
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
By BioPharma Dive staff • June 3, 2026 -
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.
By Jacob Bell • June 2, 2026 -
Emerging biotech
RallyBio tries again for reverse merger, this time with Avenzo
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
By Gwendolyn Wu • June 1, 2026 -
Akeso, Summit drug extends survival in closely watched lung cancer trial
Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.
By Jonathan Gardner • Updated June 1, 2026 -
‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
By Jonathan Gardner • May 31, 2026 -
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.
By Jacob Bell • May 29, 2026 -
News roundup
Allogene CEO to step down; Agios drug fails key test
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
By Ben Fidler • May 29, 2026 -
GSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’
The findings supporting bepirovirsen were deemed a “historic moment” by physicians and validate a drug that has “clear blockbuster potential,” according to one analyst.
By Jonathan Gardner • May 28, 2026 -
Emerging biotech
Verge, following trial failure, rebrands its AI drug discovery ambitions
Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.
By Gwendolyn Wu • May 27, 2026 -
IPO window
Cardio drugmaker Kardigan plans to go public
Founded by former MyoKardia executives, the startup has in mid- to late-stage testing three medicines licensed from the likes of Sanofi, Ionis and Bristol Myers Squibb.
By Jacob Bell • May 27, 2026 -
Obesity drugs
Kailera’s three-pronged obesity shot shows promise in early trial
As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.
By Jonathan Gardner • May 27, 2026